UK shareholder meetings calendar - next 7 days
23rd Jun 2025 14:24
| Price | 5.50p on 15-08-2025 at 18:30:04 |
|---|---|
| Change | 0.25p 4.76% |
| Buy | 6.00p |
| Sell | 5.00p |
| Last Trade: | Buy 37,500.00 at 5.5463p |
| Day's Volume: | 929,068 |
| Last Close: | 5.50p |
| Open: | 5.25p |
| ISIN: | GB0034330679 |
| Day's Range | 5.25p - 5.50p |
| 52wk Range: | 4.75p - 17.25p |
| Market Capitalisation: | £17.74m |
| VWAP: | 5.401641p |
| Shares in Issue: | 322.53m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Angle (AGL) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 37,500 | 5.5463p | Ordinary |
16:13:36 - 15-Aug-25 |
| Sell* | 70,169 | 5.40p | Ordinary |
15:43:26 - 15-Aug-25 |
| Sell* | 50,000 | 5.4888p | Ordinary |
15:12:36 - 15-Aug-25 |
| Unknown* | 7,209 | 5.50p | Ordinary |
13:05:21 - 15-Aug-25 |
| Buy* | 840 | 6.00p | Ordinary |
12:43:23 - 15-Aug-25 |
| Sell* | 25,000 | 5.41p | Ordinary |
12:29:07 - 15-Aug-25 |
| Sell* | 117,700 | 5.355p | Ordinary |
12:28:51 - 15-Aug-25 |
| Buy* | 2,480 | 5.665p | Ordinary |
12:22:46 - 15-Aug-25 |
| Sell* | 968 | 5.4689p | Ordinary |
12:02:40 - 15-Aug-25 |
| Unknown* | 50,000 | 5.50p | Ordinary |
10:44:28 - 15-Aug-25 |
Angle (AGL) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 8th Jul 2025 7:00 am | RNS-R | PARSORTIX ENABLES STUDY OF CANCER PROGRESSION |
| 30th Jun 2025 5:50 pm | RNS | Result of 2025 Annual General Meeting |
| 17th Jun 2025 7:00 am | RNS-R | EACR 2025: Innovation in AR expression profiling |
| 17th Jun 2025 7:00 am | RNS-R | EACR 2025: Data demonstrating DNA dual analysis |
| 10th Jun 2025 7:00 am | RNS-R | Novel discoveries into the biology of cancer |
| 9th Jun 2025 7:00 am | RNS | POSTING OF ANNUAL REPORT AND NOTICE OF AGM |
| 6th Jun 2025 7:00 am | RNS | Board Changes |
| 28th May 2025 7:00 am | RNS | Preliminary Results |
| 23rd May 2025 7:00 am | RNS | Notice of Results |
| 28th Apr 2025 7:00 am | RNS-R | RESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME |